PEA in Functional Dyspepsia

Dyspepsia and Other Specified Disorders of Function of Stomach Clinical Trial

Official title:
THE EFFECT OF DIETARY SUPPLEMENTATION WITH PALMITOYLETHANOLAMIDE ON GASTROINTESTINAL SYMPTOMS IN FUNCTIONAL DYSPEPSIA PATIENTS.

Status Recruiting

Clinical Trial Summary

The goal of this placebo controlled randomized double blind interventional study is to assess the effect of palmitoylethanolamide supplementation in patients with functional dyspepsia The main questions it aims to answer are: - The efficacy of PEA on functional dyspepsia symptoms measured using the LPDS questionnaire - The effect of PEA on duodenal mucosal permeability. Participants will receive an 8-week during treatment with PEA 3x400 mg per day or placebo 3 times per day.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Dyspepsia
Dyspepsia and Other Specified Disorders of Function of Stomach

Clinical Trial Details

NCT number	NCT05877781
Study type	Interventional
Source	Universitaire Ziekenhuizen KU Leuven
Contact
Status	Recruiting
Phase	N/A
Start date	November 29, 2021
Completion date	March 1, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00248651` - Functional Dyspepsia Treatment Trial	Phase 2/Phase 3
Recruiting	`NCT05880199` - BSGM to Evaluate Patients With GI Symptoms
Completed	`NCT04204421` - ESM in Functional Dyspepsia	N/A